以下ピックアップしたのを読んでもらった方が早いので
・・・つーか、私はこの全身性感染を物凄く恐れている(脳神経系や血液・循環器系を標的にして免疫システムをグチャグチャにされるのって即落命より酷くない?!)ので、絶対に感染を阻止すべくアレコレ日常でやってるわけですが・・・
まず、実は2021年の12月に「そもそもコロナ全身性に感染してるやんけ」が出ます。
オミクロンが全身性になったとか言われる以前、オミクロン発生直前のちゃぶ台返しでした。https://t.co/QXyfnovinD— ramos2 (@ramos262740691) January 22, 2023
が、一年間アクセプトされず、あまりTweetもされなかった。なんででしょうね?
(個人的にアクセプト版、そんなにプレプリントの時と変わらない気がしています…)今年秋になってアクセプトされてから急に出回ります。なんだみんな全身性潜伏感染の可能性知らなかったのねと。https://t.co/MIkG9ByzhQ
— ramos2 (@ramos262740691) January 22, 2023
それと同時に「そもそも新コロって…」という武漢株の頃の(解析に時間かかる系の)データがある程度まとまって出てきた感があったのが2022年11-12月でした。
それがこのスレのきっかけです。
— ramos2 (@ramos262740691) January 22, 2023
で、その解剖論文のインフルエンザーさんのスレがこちらと(人の労力を借りパクするスタイル)https://t.co/sHtQk7KyIK
— ramos2 (@ramos262740691) January 22, 2023
●SARS-CoV-2は脳を含む各種臓器に長期感染しうる
SARS-CoV-2は1) ACE2とTMPRSS2を介した感染、2) ACE2とカテプシンLを介した感染、3) furinとNPR1を介した感染など複数の感染経路があり、当初よりもより多くの細胞に感染する事が可能である事が分かっています。— influenzer (@influenzer3) January 21, 2023
→44例のCOVID-19による死亡例の剖検例の解析結果です。
うち11例については脳についても検討。全例がワクチン未接種例。
結果は感染初期の死亡例において、すでに脳でのウイルス増殖がある事を確認。
発症230日後の死亡例でも脳を含む全身の臓器でウイルス増殖がある事が確認されています。— influenzer (@influenzer3) January 21, 2023
しかし興味深いのは、気道以外では免疫応答による炎症所見は見られず、ウイルスによる細胞障害も認めていなかったという事実です。
— influenzer (@influenzer3) January 21, 2023
病態についての謎はさらに深まったと言えますが、本感染症が単なる呼吸器感染症ではなく、全身感染症である事。
そして、それは長期持続(潜伏?)感染となりうる事が分かったという点が重要なポイントかと思います。
Long COVIDの病態解明につながる知見かもしれません。— influenzer (@influenzer3) January 21, 2023
SARS-CoV-2 infection and persistence in the human body and brain at autopsyhttps://t.co/zlEo4bobX1
— influenzer (@influenzer3) January 21, 2023
◆SARS-CoV-2 infection and persistence in the human body and brain at autopsy【Nature 2022年12月14日】
Abstract
Coronavirus disease 2019 (COVID-19) is known to cause multi-organ dysfunction during acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with some patients experiencing prolonged symptoms, termed post-acute sequelae of SARS-CoV-2. However, the burden of infection outside the respiratory tract and time to viral clearance are not well characterized, particularly in the brain. Here we carried out complete autopsies on 44 patients who died with COVID-19, with extensive sampling of the central nervous system in 11 of these patients, to map and quantify the distribution, replication and cell-type specificity of SARS-CoV-2 across the human body, including the brain, from acute infection to more than seven months following symptom onset. We show that SARS-CoV-2 is widely distributed, predominantly among patients who died with severe COVID-19, and that virus replication is present in multiple respiratory and non-respiratory tissues, including the brain, early in infection. Further, we detected persistent SARS-CoV-2 RNA in multiple anatomic sites, including throughout the brain, as late as 230 days following symptom onset in one case. Despite extensive distribution of SARS-CoV-2 RNA throughout the body, we observed little evidence of inflammation or direct viral cytopathology outside the respiratory tract. Our data indicate that in some patients SARS-CoV-2 can cause systemic infection and persist in the body for months.
Main
COVID-19 has respiratory and non-respiratory manifestations, including multi-organ failure and shock among patients with severe and fatal disease. Some individuals who survive experience post-acute sequelae of SARS-CoV-2, also known as long COVID. Although autopsy studies of fatal COVID-19 cases support the ability of SARS-CoV-2 to infect multiple organs, extrapulmonary organs often lack histopathological evidence of virally mediated injury or inflammation. The paradox of infection outside the respiratory tract without injury or inflammation raises many pathogen- and host-related questions.
To investigate the cellular tropism, replication competence, persistence and evolution of SARS-CoV-2 in humans, and to look for associated histopathology in infected tissues, we carried out autopsies on 44 COVID-19 cases. Our approach focused on timely, systematic and comprehensive tissue sampling and preservation for complementary analyses. We carried out droplet digital polymerase chain reaction (ddPCR) for detection and quantification of SARS-CoV-2 nucleocapsid (N) gene targets and in situ hybridization (ISH) to validate the ddPCR findings and determine the cellular tropism of SARS-CoV-2. Immunofluorescence (IF) and chromogenic immunohistochemistry (IHC) were used to further validate the presence of SARS-CoV-2 in the brain. We carried out quantitative real-time PCR with reverse transcription (RT–qPCR) to detect subgenomic RNA, a marker suggestive of recent virus replication, and demonstrated replication-competent SARS-CoV-2 in selected respiratory and non-respiratory tissues, including the brain, by virus isolation in traditional and modified Vero E6 cell culture. In six individuals, we measured the diversity and anatomic distribution of intra-individual SARS-CoV-2 spike gene variants using high-throughput, single-genome amplification and sequencing (HT-SGS).
We categorized autopsy cases as early (n = 17), mid (n = 13) or late (n = 14) by illness day (d) at the time of death, being ≤d14, d15–30 or ≥d31, respectively. We defined persistence as the presence of SARS-CoV-2 RNA among late cases. We analysed and described our results in terms of respiratory and non-respiratory tissues to quantify and statistically compare SARS-CoV-2 RNA levels across tissues and cases.